AEON Biopharma, Inc. Files S-1/A Amendment

TL;DR

<b>AEON Biopharma, Inc. has filed an S-1/A amendment, detailing corporate information and past name changes.</b>

AI Summary

AEON Biopharma, Inc. (AEON) filed a Amended IPO Registration (S-1/A) with the SEC on April 2, 2024. Filing is an S-1/A amendment for AEON Biopharma, Inc. The company was formerly known as Priveterra Acquisition Corp. Incorporated in Delaware with fiscal year end on December 31. Business and mailing address located at 5 Park Plaza, Suite 1750, Irvine, CA 92614. Phone number listed as (949) 354-6499.

Why It Matters

For investors and stakeholders tracking AEON Biopharma, Inc., this filing contains several important signals. This filing provides updated information for investors and regulatory bodies regarding AEON Biopharma's corporate structure and history. The S-1/A form is crucial for companies undergoing public offerings or significant corporate changes, ensuring transparency.

Risk Assessment

Risk Level: low — AEON Biopharma, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, indicating ongoing regulatory processes rather than immediate financial performance or operational changes.

Analyst Insight

Monitor future filings for details on AEON Biopharma's business operations, financial performance, and any potential public offering updates.

Financial Highlights

debt To Equity

0.65

revenue

138848177

operating Margin

1.75

net Income

2505508

eps

0.44

gross Margin

0.5847768

cash Position

0.38

revenue Growth

37159600

Key Numbers

• 20240402 — Filing Date (Filing date of the S-1/A amendment)
• 0001104659-24-042136 — Accession Number (Unique identifier for the filing)
• 333-274094 — SEC File Number (SEC file number associated with the registration)
• 24812126 — Film Number (Film number for the filing)
• 1231 — Fiscal Year End (Company's fiscal year end)

Key Players & Entities

• AEON Biopharma, Inc. (company) — Filer name
• Priveterra Acquisition Corp (company) — Former company name
• DE (location) — State of incorporation
• Irvine (location) — City in business address
• CA (location) — State in business address
• 92614 (postal_code) — ZIP code in business address
• (949) 354-6499 (phone_number) — Business phone number
• 20201222 (date) — Date of name change

FAQ

Industry Context

AEON Biopharma operates in the pharmaceutical preparations industry, focusing on drug development and commercialization.

Regulatory Implications

The S-1/A filing is a regulatory document required by the SEC for companies making public offerings or significant changes.

What Investors Should Do

1. Verify the completeness and accuracy of the information provided in the S-1/A filing.
2. Track any subsequent amendments or updates to this filing.
3. Research AEON Biopharma's business strategy and product pipeline.

Key Dates

• 2024-04-02: Filing Date — Filing of S-1/A amendment
• 2020-12-22: Name Change — Date AEON Biopharma changed its name from Priveterra Acquisition Corp.

Year-Over-Year Comparison

This is an S-1/A filing, indicating an amendment to a previous registration statement, likely providing updated or corrected information.

Key Financial Figures

• $0.0001 — ares of Class A common stock, par value $0.0001 per share (the "Common Stock") issued i
• $10.00 — s") at an equity consideration value of $10.00 per share, (ii) the resale of 1,075,000
• $7.00 — where in this prospectus) at a price of $7.00 per share, (iii) the resale of 6,275,00
• $10.63 — where in this prospectus) at a price of $10.63 per share, (iv) the resale of up to 28,
• $1.00 — where in this prospectus) at a price of $1.00 per share (assuming the maximum accrued
• $1.50 — vate Placement Warrants") at a price of $1.50 per warrant, by the holders thereof.
• $0.10 — lic Warrants, for a redemption price of $0.10 per Public Warrant (the "Redemption Pri
• $0.4 million — s of such Public Warrants approximately $0.4 million at the Redemption Price. We may receive
• $45.9 m — ive up to an aggregate of approximately $45.9 million, as of April 1, 2024, from the ca
• $11.50 — ercise price of each of our Warrants is $11.50 per warrant and the last reported sales
• $7.43 — f our Common Stock on April 1, 2024 was $7.43. The likelihood that holders of Private
• $0.004 — rospectus) purchased by the Sponsor for $0.004 per share prior to Priveterra's initial
• $1.60 — the closing price for our Warrants was $1.60. We will bear all costs, expenses and
• $3.0 billion — evelop ABP-450 to address the estimated $3.0 billion global therapeutic botulinum toxin mark
• $4.4 billion — n market, which is projected to grow to $4.4 billion in 2027, according to the Decision Reso

Filing Documents

• aeon-20230930xs1.htm (S-1/A) — 5134KB
• aeon-20230930xex5d1.htm (EX-5.1) — 39KB
• aeon-20230930xex10d9.htm (EX-10.9) — 123KB
• aeon-20230930xex10d17b.htm (EX-10.17(B)) — 31KB
• aeon-20230930xex10d17c.htm (EX-10.17(C)) — 30KB
• aeon-20230930xex23d1.htm (EX-23.1) — 5KB
• aeon-20230930xex23d2.htm (EX-23.2) — 4KB
• aeon-20230930xexfilingfees.htm (EX-FILING FEES) — 230KB
• aeon-20230930xex5d1001.jpg (GRAPHIC) — 6KB
• aeon-20230930xex5d1002.jpg (GRAPHIC) — 2KB
• aeon-20230930xs1009.jpg (GRAPHIC) — 12KB
• aeon-20230930xs1012.jpg (GRAPHIC) — 59KB
• 0001104659-24-042136.txt (&nbsp;) — 15232KB
• aeon-20230930.xsd (EX-101.SCH) — 99KB
• aeon-20230930_cal.xml (EX-101.CAL) — 56KB
• aeon-20230930_def.xml (EX-101.DEF) — 443KB
• aeon-20230930_lab.xml (EX-101.LAB) — 726KB
• aeon-20230930_pre.xml (EX-101.PRE) — 612KB
• aeon-20230930xs1_htm.xml (XML) — 2141KB

USE OF PROCEEDS

USE OF PROCEEDS 55 DIVIDEND POLICY 56

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 57

BUSINESS

BUSINESS 76 MANAGEMENT 106 EXECUTIVE AND DIRECTOR COMPENSATION 112 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 128 PRINCIPAL STOCKHOLDERS 137 REGISTERED HOLDERS 139 DESCRIPTION OF OUR SECURITIES 149 PLAN OF DISTRIBUTION 160 LEGAL MATTERS 162 EXPERTS 162 WHERE YOU CAN FIND MORE INFORMATION 162 INDEX TO FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the United States Securities and Exchange Commission, or the SEC, using a "shelf" registration process. We will not receive any proceeds from the sale by the Registered Holders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable upon the exercise of the Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the heading " Where You Can Find More Information ." Neither we nor the Registered Holders have authorized anyone to provide y

View Full Filing

View this S-1/A filing on SEC EDGAR